Always room for competition, but I maintain that it won't be considered to be cost effective for BOT to pursue 1801.
It would be a very long and costly journey to embark on.
Niche? Not sure we're operating on the same definition of that word.
You've not mentioned R435 and R529.
Same MoA and resistance is not formed.
"Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. Recce’s anti-infectives are unique – their potency does not diminish even with repeated use, a common failure associated with existing drugs."
BOT Price at posting:
37.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)